ATRIAL FIBRILLATION IN OLD AGE: RISK MANAGEMENT AND FEATURES OF THE USE OF DIRECT ORAL ANTICOAGULANTS

Senile patients with atrial fibrillation (AF) are at a higher risk of thromboembolism and hemorrhage than younger patients. Three direct oral anticoagulants (DOAC), apixaban, dabigatran, and rivaroxaban, are registered in the Russian Federation and are extensively used for the prevention of stroke in patients with AF. The DOAC treatment of older patients requires considering peculiarities of these patients, the clinical situation, and the properties of individual drugs to achieve the balance of efficiency and safety and a comprehensive protection. According to the studies of real clinical practice, DOAC may have advantages over warfarin (reduced risk of fractures, diabetes mellitus, and dementia). Compliance with and constancy of the DOAC treatment are important for its efficiency, particularly in senile age. The results of clinical trials and real clinical practice studies have confirmed that rivaroxaban may provide a comprehensive protection for a senile patient with AF due to favorable indexes of efficiency and safety, a beneficial effect on the risk of coronary events and the impairment of renal function, whereas once a day dosing of rivaroxaban improves the compliance with this treatment and its constancy.